RLD2001-2

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyHypertension

Phase 1

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.

CompletedNCT05191563

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2021-07-31End: 2021-09-12Updated: 2022-01-13

Phase 3

Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

CompletedNCT04830449

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2020-10-29End: 2021-08-24Updated: 2023-09-22

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Not yet recruitingNCT07660796

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2026-07-06End: 2027-11-30Target: 256Updated: 2026-06-30